These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 4155235)

  • 21. Dihydroxyphenylacetic acid in the treatment of Parkinsonism.
    Ericsson AD; McCann DS
    Adv Neurol; 1974; 5():301-6. PubMed ID: 4440578
    [No Abstract]   [Full Text] [Related]  

  • 22. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic uses and side effects of L-dopa.
    Boshes B
    Adv Intern Med; 1972; 18():219-49. PubMed ID: 4576081
    [No Abstract]   [Full Text] [Related]  

  • 24. "Off period" dystonia and "on period" choreoathetosis in levodopa-treated patients with Parkinson's disease.
    Lees AJ; Shaw KM; Stern GM
    Lancet; 1977 Nov; 2(8046):1034. PubMed ID: 72935
    [No Abstract]   [Full Text] [Related]  

  • 25. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
    Tissot R; Gaillard JM; Guggisberg M; Gauthier G; de Ajuriaguerra J
    Presse Med (1893); 1969 Apr; 77(17):619-22. PubMed ID: 5785081
    [No Abstract]   [Full Text] [Related]  

  • 26. [Abnormalities of catecholamine metabolism in Parkinson's disease (author's transl)].
    Nagatsu T
    Tanpakushitsu Kakusan Koso; 1981 Aug; 26(11):1781-8. PubMed ID: 6117927
    [No Abstract]   [Full Text] [Related]  

  • 27. Letter: Dyskinesias during levodopa therapy.
    Tolosa ES; Maritn WE; Cohen HP
    Lancet; 1975 Jun; 1(7921):1381-2. PubMed ID: 48968
    [No Abstract]   [Full Text] [Related]  

  • 28. Unexpected findings with apomorphine and their possible consequences.
    Cotzias GC; Mena I; Papavasiliou PS; Mendez J
    Adv Neurol; 1974; 5():295-9. PubMed ID: 4440577
    [No Abstract]   [Full Text] [Related]  

  • 29. Levodopa, motor complications and disease progression.
    Deleu D
    J Neurol Sci; 2008 Oct; 273(1-2):155-6; author reply 156-7. PubMed ID: 18620710
    [No Abstract]   [Full Text] [Related]  

  • 30. [L-dopa-induced movement disorders in Parkinson disease. Amantadine improves dyskinesia].
    MMW Fortschr Med; 2001 May; 143 Suppl 2():93. PubMed ID: 11434272
    [No Abstract]   [Full Text] [Related]  

  • 31. L-dopa-resistant Parkinsonism due to dopa decarboxylase deficiency?
    Jankovic J
    Ann Neurol; 1981 Jul; 10(1):64-5. PubMed ID: 7271235
    [No Abstract]   [Full Text] [Related]  

  • 32. Mechanism of action of short- and long-term L-DOPA treatment in parkinsonism: role of the surviving nigrostriatal dopaminergic neurons.
    Melamed E; Hefti F
    Adv Neurol; 1984; 40():149-57. PubMed ID: 6695591
    [No Abstract]   [Full Text] [Related]  

  • 33. [Two years experience with L-DOPA in association with a decarboxylase inhibitor].
    Siegfried J
    Rev Neurol (Paris); 1970 Apr; 122(4):243-8. PubMed ID: 5472041
    [No Abstract]   [Full Text] [Related]  

  • 34. Double-blind comparison of levodopa and procyclidine in parkinsonism, with illustrations of levodopa-induced movement disorders.
    Timberlake WH
    Neurology; 1970 Dec; 20(12):31-5. PubMed ID: 4924342
    [No Abstract]   [Full Text] [Related]  

  • 35. Nosological concept of juvenile parkinsonism with reference to the dopa-responsive syndrome.
    Yokochi M
    Adv Neurol; 1993; 60():548-52. PubMed ID: 8420189
    [No Abstract]   [Full Text] [Related]  

  • 36. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of parkinsonism by L-dopa and dopa-decarboxylase inhibitor in a single tablet].
    Sarova-Pinhas I; Braham J
    Harefuah; 1974 Sep; 87(5):208-10. PubMed ID: 4435614
    [No Abstract]   [Full Text] [Related]  

  • 38. Letter: Diphasic dyskinesia during levodopa therapy.
    Barbeau A
    Lancet; 1975 Mar; 1(7909):756. PubMed ID: 47527
    [No Abstract]   [Full Text] [Related]  

  • 39. Levodopa: past, present, and future.
    Hauser RA
    Eur Neurol; 2009; 62(1):1-8. PubMed ID: 19407449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. L-dopa induced dyskinesias in 152 patients with Parkinson's disease.
    Mones RJ; Elizan TS; Siegel G
    Trans Am Neurol Assoc; 1970; 95():286-7. PubMed ID: 5514393
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.